Sage — DMSO (The Kit)
Hypothesis: DMSO is a dipolar solvent in the mitochondrial membrane environment — not a fuel, not a miracle. Education only; no topical/systemic schedules.
The Kit · Coach · Surfer · Eye · Immune
*Dimethyl **Sulfoxide** as a Membrane-State Intervention, Not a Metabolic Fuel*
*Frugal Philosophy Essay · September 2026*
***Disclaimer. ****This essay presents a metabolic and evolutionary hypothesis for educational and philosophical purposes. It is not medical advice, diagnosis, or treatment. Dimethyl **sulfoxide** is a biologically active solvent with a narrow and poorly mapped therapeutic window. Pharmaceutical-grade DMSO is FDA-approved in the United States only for **intravesical** use in interstitial cystitis. Industrial and veterinary preparations are not equivalent to pharmaceutical material and can carry contaminants across membranes. Individual responses vary widely. Readers should consult a qualified clinician before using DMSO by any route, especially in the presence of existing disease, pregnancy, eye pathology, or concurrent medications.*
I have long argued, both in clinical work and in these metabolic hypothesis essays, that the dominant paradigms of chronic disease too often target the dashboard—the observable readouts and signaling overrides—while neglecting the engine: the mitochondrial networks, autophagic machinery, membrane architecture, and redox state that actually generate metabolic health or dysfunction. DMSO has spent sixty years trapped on that dashboard. To its advocates it is a near-universal anti-inflammatory and analgesic. To its regulators it is a historically tainted solvent with one narrow approved indication and a lingering rumor of ocular toxicity. Both accounts describe real phenomena. Neither asks the upstream question that the rest of this series treats as primary: what does this molecule do to the cell’s capacity to convert fuel into ATP, to manage electron leak, and to maintain the membrane environment in which oxidative phosphorylation actually occurs?
The molecule itself invites the wrong conversation. Dimethyl sulfoxide is a small, polar, aprotic solvent centered on a sulfur-oxygen dipole. It mixes with water and with lipids. It accepts hydrogen bonds. It crosses skin, mucosa, cornea, and organelle membranes with unusual speed. A fraction is oxidized, principally by CYP2E1, to dimethyl sulfone—DMSO₂, better known in the supplement trade as MSM. A fraction is reduced to dimethyl sulfide, which leaves on the breath and the skin and produces the characteristic garlic or oyster odor that has done as much as any regulator to keep the compound in the realm of folklore. Neither metabolite is a meaningful caloric substrate. DMSO does not enter the energy equation as glucose does, or as palmitate does, or as β-hydroxybutyrate does. Calories, as I have written elsewhere, arrive wrapped in instructions. DMSO arrives wrapped in solvent physics.
The Hypothesis
The hypothesis is straightforward. DMSO is not a metabolic fuel and not a hormone. It is a concentration-dependent membrane-state intervention that transiently alters the solvent environment of bilayer lipids, proteins, and interfacial water. At low occupancy this perturbation can thin membranes, change local water structure, activate cytochrome oxidase by structural rather than biosynthetic means, scavenge hydroxyl radical at the membrane–water interface, and reduce the inflammatory programs that constitute an expensive compensatory mode. At higher occupancy the same physics forms pores, dehydrates intermembrane space, collapses mitochondrial membrane potential, releases cytochrome c, and converts a radical sink into a radical source. The clinical phenomenology of DMSO—analgesia, reduced swelling, rapid systemic distribution, garlic odor, and the historical oscillation between miracle and toxin—is the organism-level expression of this dose curve acting on tissues of unequal mitochondrial density and unequal spare respiratory capacity.
Two dominant alternative frameworks miss the upstream driver. The first treats DMSO as a cure-all whose mechanism is sufficiently captured by “anti-inflammatory” and “penetrant.” That account explains why a knee can feel better and why a co-administered molecule appears in blood. It does not explain why the same compound, a few percentage points higher in local concentration, swells mitochondria, drops ΔΨm, and kills astrocytes in culture. The second treats DMSO as an industrial solvent whose biological effects are noise to be minimized in laboratory protocols and whose popular use is a regulatory embarrassment. That account explains the 1960s FDA panic and the paucity of modern controlled trials. It does not explain why isolated, tightly coupled mitochondria can be protected from freeze–thaw loss of respiratory control by the same molecule, nor why a single intraperitoneal dose in the rat can raise hepatic cytochrome oxidase activity several-fold for days without a commensurate increase in cytochrome a/a₃ content.
A more parsimonious framework places membrane physics and mitochondrial integrity at the center. DMSO does not restore ancestral fuel architecture. It does not rebuild mitophagy. It does not raise physical-activity level or metabolic scope. It does not repair the nested partnership between the alphaproteobacterial endosymbiont and the gut consortium. It changes the housing of the engine. Whether that change is protective or destructive is a function of concentration, duration, cell type, and the pre-existing quality of the mitochondrial population on which it acts.
What the Molecule Is, and Where It Sits in the Holobiont
The eukaryotic cell and the human organism it constitutes are not free-floating metabolic engines. They are nested symbionts. The inner partner is the mitochondrion, the permanent bacterial inheritance of an ancient endosymbiosis, still running oxidative phosphorylation on membranes whose lipid composition, cardiolipin geometry, and iron–sulfur wiring retain the signature of that ancestry. The outer partner is the gut community, an ecological organ whose collective genome encodes the enzymes the host never acquired. Fuel is the substrate that either respects or assaults this architecture. DMSO is not fuel. It is a visitor to the same architecture—an organosulfur species that both partners already know how to touch.
DMSO, DMS, and DMSO₂ participate in a planetary sulfur cycle that long predates medicine. Marine and terrestrial microbes oxidize and reduce these species; DMSO can serve as a terminal electron acceptor in anaerobic respiration; DMS is a climate-active gas; DMSO₂ appears in human blood, cerebrospinal fluid, urine, and even brain as a normal constituent, derived from diet, from microbial co-metabolism of methanethiol and related one-carbon sulfur compounds, and from host oxidation of DMSO. The human metabolome already contains the end product that supplement marketing calls MSM. Administration of DMSO is therefore not the introduction of an alien chemistry. It is a large, abrupt pulse through a redox loop that the holobiont already runs at trace flux.
That fact has two implications that the popular literature usually conflates. First, some of the lingering systemic effect after parent DMSO has cleared is DMSO₂. MSM does not share DMSO’s membrane-penetration and carrier properties. Treating oral or topical DMSO as a clever way to load MSM is pharmacokinetically inefficient and adds the solvent risk that MSM itself does not carry. Second, sulfur is not optional decoration in the engine. The iron–sulfur clusters of Complexes I, II, and III are the actual electron wire of oxidative phosphorylation. Glutathione, the cell’s principal thiol buffer, is a sulfur story. Methionine sulfoxide reductases already reduce a range of methyl sulfoxides. A molecule that both scavenges hydroxyl radical and participates in organosulfur redox is at least in the correct chemical neighborhood. Neighborhood is not identity. Presence in a pathway is not restoration of the pathway.
The outer symbiont is not a spectator. Gut organisms reduce DMSO to DMS. Host microsomes oxidize DMSO to MSM. The balance between those fates depends on dose, oxygen tension, CYP2E1 activity, and the composition of the colonic community. A large oral pulse of DMSO is therefore also an ecological input to the gut consortium—an electron acceptor for some taxa, a source of volatile sulfur for others, and a change in the luminal solvent that has not been mapped with the care the holobiont deserves. Any metabolic hypothesis that treats DMSO as a purely host-side anti-inflammatory is incomplete on the same grounds that a hypothesis of fuel is incomplete if it ignores the biota.
Not a Fuel: Energy Flux Versus Solvent Environment
Energy flux, in the sense that matters for organismal health, is the rate at which substrate is oxidized to usable ATP while redox homeostasis is maintained and membranes remain competent to hold a proton motive force. High flux in a well-coupled system is fitness. High flux through a leaking, PUFA-peroxidized, Complex-I-impaired system is the progressive loss of ATP-generating capacity I have described as the root of aging. DMSO does not increase the former by supplying carbon. Its caloric contribution is negligible. What it can change is the physical context in which flux occurs.
Membranes are not inert bags. They are the working surface of the engine. The inner mitochondrial membrane houses the respiratory supercomplexes; its curvature, thickness, hydration, and cardiolipin composition determine whether electrons move through Complexes I–IV with controlled leak or spill to oxygen as superoxide. Interfacial water is part of that surface. DMSO, as a hydrogen-bond acceptor that mixes with both phases, reorganizes that water and partitions into the headgroup region in a concentration-dependent sequence that physical chemists have mapped with some care. At low mole fraction the bilayer thins. At higher mole fraction pores form as the solvent interacts with polar phospholipids. Beyond a further threshold the membrane disintegrates in the hygroscopic medium, and at still higher occupancy lipid membranes dehydrate and intermembrane distances fall.
Those are not “side effects.” They are the primary pharmacology. Every downstream claim—analgesia, radical scavenging, drug carriage, mitochondrial activation, mitochondrial collapse—is a consequence of a small dipolar solvent occupying the same physical space in which the electron-transport chain has to work. The metabolic hypothesis of DMSO is therefore a hypothesis about solvent occupancy of the engine’s housing, not a hypothesis about a new substrate entering the TCA cycle.
The Mitochondrial Dose Curve
If the engine is the question, the dose curve is the answer.
At low concentration, the record is not empty and not uniformly hostile. A single intraperitoneal dose of DMSO in the rat (on the order of 2.75 g/kg) stimulated hepatic cytochrome oxidase activity two- to five-fold, and the elevation persisted for as long as five days. Spectrophotometric cytochrome a/a₃ content rose only about ten percent in the same interval. Addition of DMSO, or of a related metabolite, to isolated liver mitochondria reproduced a two- to three-fold increase in oxidase activity. The parsimonious reading is activation by structural alteration of the membrane, not de novo synthesis of Complex IV. In a separate and older line of work, DMSO protected tightly coupled plant mitochondria from the loss of respiratory control that otherwise follows freezing in liquid nitrogen. Isolated mitochondria, in that experiment, were a model of membrane injury and of its prevention. The molecule that later became a cryoprotectant for cells was already a cryoprotectant for the organelle.
In H9c2 cardiomyoblasts, six days of exposure at or below 0.5 percent raised respiratory control ratio and viability relative to untreated cells. Coupling efficiency did not rise in parallel; in some conditions it drifted downward, which is a useful warning. A tighter apparent control ratio is not the same thing as a cleaner engine. It can reflect a change in leak, in ATP demand, or in the fraction of the mitochondrial population that is still participating. The metabolic reading of a higher RCR is therefore incomplete until spare capacity, membrane potential, and ROS production are measured in the same system.
At higher concentration the same literature becomes unambiguous. In cultured cortical astrocytes, 1 percent DMSO for twenty-four hours was already sufficient to swell mitochondria, impair ΔΨm, increase mitochondrial superoxide, release cytochrome c, and activate caspase-3. At 5 percent the ultrastructure collapsed: loss of cristae, vacuolar remnants, cell death. In cardiomyoblasts, 3.7 percent drove apoptosis through mitochondrial dysfunction and oxidative stress and erased the RCR advantage seen at lower doses. In MCF-7 cells, even substantially lower percentages reduced maximal respiration and ATP-linked respiration; the glycolytic, high-turnover phenotype saw the solvent as an insult earlier than the more quiescent myoblast. Human skeletal-muscle fibers subjected to DMSO cryopreservation lose oxidative phosphorylation capacity, with Complex I more affected than Complex II—the complex that, in the ROS-leak account of chronic disease, is already the most vulnerable node in a failing chain.
Cell type is not a detail. Photoreceptors, cardiac myocytes, type I skeletal fibers, and renal tubular cells live near the edge of their ATP budget. A solvent occupancy that a glycolytic tumor cell or a cultured fibroblast can tolerate may be the occupancy that drops spare capacity in a tissue that has none to spare. This is why the eye belongs in the argument, and why a single concentration quoted as “safe in culture” is not a biological constant.
The dose curve also explains the historical whiplash. Early clinical enthusiasm applied material whose local concentration, after topical or subcutaneous use, was never measured at the mitochondrion. Early toxicology applied high systemic exposures to dogs and rabbits and found lens changes. Both observations can be true. They are different points on the same curve, read out in tissues of different mitochondrial density. The regulatory conclusion that followed—treat the compound as radioactive and walk away—was a dashboard decision. It left the engine question unasked for two generations.
ROS: Sink and Source
The oxidative-damage theory of aging, as I have argued in the companion essay on ATP-generating capacity, describes a real phenomenon while mistaking a downstream process for a root. Reactive oxygen species from the electron-transport chain damage mtDNA, iron–sulfur centers, cardiolipin, and nuclear genomes. That damage reduces ATP output, which reduces the energy available for quality control, which allows further damage. DMSO intersects this loop at two opposite points depending on occupancy.
Hydroxyl radical is the species DMSO is classically said to scavenge. That chemistry is not folklore. A small, membrane-partitioning OH• sink sitting at the bilayer–water interface is a plausible short-term buffer against the most destructive product of Fenton chemistry near the inner membrane. In a cell whose constraint is already ROS damage to ETC proteins, a transient reduction in that particular radical load can look like anti-inflammatory magic on the dashboard: less NF-κB drive, less NLRP3 activation by mitochondrial ROS, less cytokine transcription, less pain. MSM literature points in a similar direction, with the important caveat that MSM appears to suppress mitochondrial generation of oxidants in stimulated neutrophils rather than neutralizing them in a cell-free system. The target, again, is the organelle, not the test tube.
The opposite limb of the curve is equally chemical. Once DMSO occupancy is high enough to swell the matrix, drop ΔΨm, and disorganize cristae, electron leak increases. The molecule that was scavenging hydroxyl radical is now helping to generate superoxide by wrecking the geometry of the chain that was supposed to contain it. Cytochrome c release is not an anti-inflammatory event. It is the opening of the apoptotic cascade. A therapy that buys pain relief by walking a tissue toward that threshold is not engine repair. It is a controlled injury that happens, in some patients, to silence a compensatory program on the way down.
The practical consequence for anyone who takes the metabolic philosophy seriously is that “antioxidant” is not a property of a molecule. It is a property of a molecule-plus-concentration-plus-membrane-plus-pre-existing-leak. DMSO is an antioxidant in one regime and a pro-oxidant in the next. Any protocol that cannot specify which regime it occupies is not a protocol. It is a hope.
Dashboard Effects and Why They Seduce
Pain, edema, and stiffness are expensive programs. Nociceptive signaling, vascular leak, leukocyte trafficking, and the transcriptional apparatus of innate immunity all consume ATP and divert substrate away from maintenance. In the compensatory-mode account of disease, much of what we name inflammation is the organism spending energy it does not have because the engine cannot meet demand cleanly. A molecule that reduces that spend will feel like health even if it has not added a single molecule of ATP.
DMSO’s analgesic and anti-edematous reputation is therefore not mysterious and not proof of engine repair. Rapid membrane penetration carries the solvent, and anything dissolved in it, into the interstitial and intracellular space. Local nerve excitability can fall. Radical load at the inflammatory focus can fall. The patient reports less pain. The dashboard improves. The question the rest of medicine usually stops asking—and that this series exists to keep asking—is whether spare respiratory capacity, coupling, lactate handling, and the honest phenotypic signals of cellular fitness moved in the same direction.
The carrier property deserves the same suspicion. DMSO’s ability to take other molecules across skin and mucosa is the feature that made it industrially useful and clinically tempting. It is also the feature that makes industrial-grade material a poor man’s intravenous line for whatever contaminants the drum contained. From a metabolic standpoint the carrier effect is orthogonal to fuel quality. It can deliver a useful cofactor. It can deliver a toxin. It does not, by itself, change the instruction set wrapped around a calorie. The metabolic philosophy does not forbid carriers. It refuses to confuse a carrier with a repair.
Interstitial cystitis, the one FDA-approved indication, is a useful test case precisely because it is so poorly understood. Intravesical DMSO almost certainly acts as a local solvent and mild chemical denervating agent on a urothelium and lamina propria that are inflamed, leaky, and painful. That may be a rational local use. It is not evidence that systemic DMSO restores mitochondrial networks in myocardium, photoreceptor, or hepatocyte. Local solvent on a painful mucosa is dashboard management with a plausible mechanism. Generalizing from that mucosa to the organism is the error this essay exists to block.
The Eye as Canary
I have written that the eye is the canary in the coal mine of mitochondrial dysfunction, and I mean it in the literal sense that photoreceptors and retinal pigment epithelium are among the highest mitochondrial-density, highest-flux tissues in the body. The lens epithelium lives under a different but related constraint: decades of protein packing, low turnover, and continuous exposure to light-generated oxidants. Any membrane-active solvent applied to this organ is an experiment on the canary.
The 1960s lens findings in dogs and other animals at high systemic exposure were the proximate cause of the FDA’s interruption of DMSO research. Subsequent human observation in patients treated for other conditions did not reproduce a clear cataractogenic signal at the regimens then used, and the American Academy of Ophthalmology has stated that there is no reliable evidence DMSO heals cataracts, floaters, or related conditions. Both can be true. High-dose animal lens change and the absence of a human cataract drug are not contradictions. They are the two ends of a dose curve read in a high-demand tissue.
Boundaries
Not part of the Kit: industrial or veterinary DMSO. This page makes no eye-treatment claims. Map ≠ terrain. Board first: Fuel · Circadian · Strength · ETC; Kit last.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.